Neovascular Age-related Macular Degeneration Clinical Trials in West Columbia, South Carolina
8 recruitingWest Columbia, South Carolina
Showing 1–8 of 8 trials
Recruiting
Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled51 locationsNCT04853251
Recruiting
Phase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled18 locationsNCT07614776
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 2
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.15 enrolled4 locationsNCT07630649
Recruiting
Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Phase 2
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577